The Readout Loud
Business

The Readout Loud

by STAT

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

101 episodes
EN language
All Episodes
1
393: A conversation with the 'godfather' of biotech
45:05 Mar 20, 2026
2
392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA
30:51 Mar 12, 2026
3
391: Breaching the IBD efficacy ceiling, and sham surgeries
30:29 Mar 5, 2026
4
390: FDA turmoil, election intrigue, AI, and more
32:40 Feb 26, 2026
5
389: Hims' Super Bowl fallout, and the FDA reverses course
34:20 Feb 19, 2026
6
388: The FDA's refusal to review Moderna's mRNA flu vaccine
51:24 Feb 12, 2026
7
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
28:04 Feb 5, 2026
8
From Drug Story: Lipitor and Heart Disease
1:01:36 Feb 3, 2026
9
386: The high stakes for Huntington's patients
41:39 Jan 29, 2026
10
385: A measles outbreak and hospitals' financial troubles
29:47 Jan 22, 2026
11
384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
1:08:10 Jan 14, 2026
12
383: JPM to bring more deals and happy CEOs
33:35 Jan 8, 2026
13
382: Biotech's year in review
34:07 Dec 18, 2025
14
381: The future of American science and a dispatch from ASH
33:26 Dec 11, 2025
15
380: A new top drug regulator and the future of psychedelics
32:45 Dec 4, 2025
16
379: How Mark Cuban plans to ‘f— up’ health care
37:10 Nov 20, 2025
17
378: Merck's heart disease win and the FDA's new drug regulator
36:06 Nov 13, 2025
18
377: Melodrama at the FDA and the Pfizer-Novo bidding war
31:21 Nov 6, 2025
19
376: BridgeBio’s great week and Moderna’s unraveling
38:12 Oct 30, 2025
20
375: Startups push the FDA and biotech booms in North Carolina
29:12 Oct 23, 2025
21
374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
34:10 Oct 16, 2025
22
373: Party in biotech land and AstraZeneca’s miscalculation
45:40 Oct 9, 2025
23
372: A pharma C-suite shakeup and Trump's deal with Pfizer
28:05 Oct 2, 2025
24
371: A gene therapy success in Huntington's and Trump's autism announcement
42:32 Sep 25, 2025
25
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
37:21 Sep 18, 2025
26
369: Trump, Chinese biotech, and an industry career reshaped by illness
36:33 Sep 11, 2025
27
368: New stakes in the vaccine dispute and a boost for biotech
27:27 Sep 4, 2025
28
367: The ouster of CDC's director, biotech venture firm rankings
28:35 Aug 28, 2025
29
366: Viking’s obesity flop, ‘pharma to table’ drug sales
25:28 Aug 21, 2025
30
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
27:45 Aug 14, 2025
31
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
37:55 Aug 7, 2025
32
363: What Vinay Prasad’s ouster means for biotech and the FDA
44:23 Jul 31, 2025
33
362: A mother’s perspective on Sarepta’s gene therapy halt
36:55 Jul 24, 2025
34
361: Inside an FDA drug rejection, and layoffs at Sarepta
43:01 Jul 17, 2025
35
360: NIH grant cuts, FDA transparency questions and biotech M&A
25:18 Jul 10, 2025
36
359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
34:29 Jun 26, 2025
37
358: FDA's gene therapy turmoil, and an alternative model for funding research
30:12 Jun 19, 2025
38
357: The upheaval of CDC's vaccine panel, and drug pricing confusion
45:02 Jun 12, 2025
39
356: An AI experiment at the FDA & Novo trailing in the obesity drug race
33:05 Jun 5, 2025
40
355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview
36:55 May 29, 2025
41
354: Uncertainty in CRISPR world and the start of more M&A
41:30 May 22, 2025
42
353: Trump's drug-pricing plan and a potential Theranos 2.0
25:47 May 15, 2025
43
352: A firebrand takes oversight of vaccines, gene therapies
26:28 May 8, 2025
44
351: It's gonna be May (in biotech)
35:19 May 1, 2025
45
350: Pharma tariffs, and a 'sunshine day' for biotech stocks
31:40 Apr 24, 2025
46
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
40:55 Apr 10, 2025
47
348: Cuts, ousters and drama at the FDA
31:10 Apr 3, 2025
48
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
31:25 Mar 27, 2025
49
346: Zealand's obesity strategy and Immunovant's curious development plan
42:34 Mar 20, 2025
50
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
31:00 Mar 13, 2025
Select an episode
0:00 0:00